.ANALYSIS FEATURE.16 October 2024.
In the NIAGARA litigation, the addition of perioperative durvalumab to basic treatment for muscle-invasive bladder cancer cells improved event-free and also generally survival, noting a brand-new procedure possibility for this disorder.